Precision antimicrobial medicine
Why replace antibiotics when we can make them work better?
Resistance often doesn't mean the antibiotic is finished. It means it needs a partner.1 The platform reads the bacterial genome of a resistant isolate and returns the adjunct most likely to restore its response — bacterial DNA fingerprint in, matched adjunct in minutes, not months. Today that runs as a research tool with our lab and hospital collaborators. The diagnostic comes next, as validation clears.
Research use only. Not a diagnostic device.
phage is live today. β-lact. inhibitor and depolymerase are ranked here but not yet clinically actionable.
Every ranking is confirmed by the ordering laboratory against its own isolate before any use.
The problem
It isn't a science problem. It's an economics one.
1.27 million deaths a year, one in six infections already resistant, while the pipeline that should answer it can't pay for itself.
Cost of one new antibiotic.
What it earns back: a fraction.
None in ~three decades.
Achaogen, after approval.
How it works
DNA fingerprint in. Matched adjunct out.
Matching an adjunct to a patient's isolate has been manual work taking two to six months. We automate it: phages today, more modalities ranked alongside as they clear validation.
Sequence the isolate
Upload the whole-genome sequence or PCR profile of the resistant strain.
Match the library
The model ranks 4,000+ phages, plus β-lactamase inhibitors and depolymerases, against the strain.
Confirm and source
The lab confirms the shortlist and sources the phage from any bank. Supply-agnostic.
Team
Built by the people closest to the problem.
Both founders lost a parent to a drug-resistant infection. We’re building with support from clinical and academic collaborators at CHUV, HUG and Apollo Hospitals.
Leadership
PhD, EPFL. Ex-infectious disease product lead, with product now in trials. Leads strategy & fundraising.
PhD, EPFL. Leads regulatory strategy, quality systems and market access.
PhD, Institut Pasteur. 15+ years in infectious disease; leads scientific strategy and platform validation.
Extended team
MSc in Computer Science. Leads the AI core for therapy matching: biological data into clinical predictions.
MSc in Bioinformatics. Builds scalable bioinformatics pipelines and genomic analysis tools for the platform.
PhD in Microbiology. Leads the strain bank and diagnostics; expert in microbial ecology & host–microbe interactions.
MSc in Clinical Laboratory Research. Ensures high-quality experimental execution and reliable data generation in the lab.
PhD in Molecular Genetics. Drives partnerships with hospitals, research institutions and industry for clinical access.
30+ years in drug discovery, IP strategy and translational research.
35+ years across biotech, MedTech and pharma; regulatory strategy, scaling and global operations.
Director of Microbiology, CHUV; expert in antimicrobial resistance and clinical microbiology.
Co-funded by Innosuisse and run with the University of Geneva and Geneva University Hospitals, this project co-develops and improves a rapid test that selects the right phage adjunct for a resistant isolate inside a single day shift, and works out how that result reaches the treating team, from the microbiology bench into the hospital’s existing clinical workflow.
Clinical microbiology and rapid diagnostics. Anchors the test in hospital routine and the route to clinical validation.
Genomics and molecular microbiology. Leads assay development and strain characterisation on the project.
Engineering phages and phage derivatives against biofilms, the form bacteria take when they stop responding to antibiotics altogether. Candidates are designed in silico, then screened in the wet lab at high throughput, so the promising designs are identified early in the cycle rather than at the end of it.
Microbiology at the Department of Pharmaceutical Sciences, Novara. Works on anti-adhesive and anti-biofilm agents, and the assays that test them against staphylococcal and Candida biofilms.
Associate professor of medicinal chemistry. Develops computational methods to find new lead compounds; co-founded the spin-out IXTAL in 2014.
Professor of microbiology and head of the microbiology laboratories at the Institute of Life Sciences. Sequences phage genomes to establish the genetic passport that clears a phage for clinical use.
Recognition & support
Backed by the programmes betting on us.
Accelerators, innovation agencies and public bodies supporting the work, plus a Best Innovation Award at Phage Therapy 2025.
Contact
Tell us what you're up against.
Labs, phage banks, hospital ID services, investors: we answer every message ourselves.
- Emailinfo@precisehealth.io
- Locations
- Sion
- Lausanne
- Washington, DC
Send a message
Reference
- Adjunct and combination strategies can restore the activity of existing antibiotics against resistant strains, e.g. β-lactamase inhibitors (co-amoxiclav, a WHO essential medicine) and efflux-pump inhibitors. Reviewed in Yin et al., MicrobiologyOpen (2026), doi:10.1002/mbo3.70233; and JACS Au (2022), doi:10.1021/jacsau.2c00532. Reversibility is strain- and mechanism-dependent, not universal.